{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:43:59Z","timestamp":1787021039578,"version":"build-2736575974"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T00:00:00Z","timestamp":1633564800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T00:00:00Z","timestamp":1633564800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Joint Federal Committee - Innovation Fund","award":["01NVF16021"],"award-info":[{"award-number":["01NVF16021"]}]},{"name":"Federal Institute for Drugs and Medical Devices and University Hospital of Bonn","award":["IV-16703\/68502\/2016-2020"],"award-info":[{"award-number":["IV-16703\/68502\/2016-2020"]}]},{"name":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte (BfArM)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Adverse drug reactions (ADRs) in the pediatric population may differ in types and frequencies compared to other populations. Respective studies analyzing ADR reports referring to children have already been performed for certain countries. However, differences in drug prescriptions, among others, complicate the transferability of the results from other countries to Germany or were rarely considered. Hence, the first aim of our study was to analyze the drugs and ADRs reported most frequently in ADR reports from Germany referring to children contained in the European ADR database (EudraVigilance). The second aim was to set the number of ADR reports in relation to the number of drug prescriptions. These were provided by the Research Institute for Ambulatory Health Care in Germany.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>For patients aged 0\u201317\u2009years 20,854 spontaneous ADR reports were received between 01\/01\/2000\u201328\/2\/2019. The drugs and ADRs reported most frequently were identified. Stratified analyses with regard to age, sex and drugs used \u201coff-label\u201d were performed. Reporting rates (number of ADR reports\/number of drug prescriptions) were calculated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Methylphenidate (5.5%), ibuprofen (2.3%), and palivizumab (2.0%) were most frequently reported as suspected. If related to the number of drug prescriptions, the ranking changed (palivizumab, methylphenidate, ibuprofen). Irrespective of the applied drugs, vomiting (5.4%), urticaria (4.6%) and dyspnea (4.2%) were the ADRs reported most frequently. For children aged 0\u20131\u2009year, drugs for the treatment of nervous system disorders and foetal exposure during pregnancy were most commonly reported. In contrast, methylphenidate ranked first in children older than 6\u2009years and referred 3.5 times more often to males compared to females. If age- and sex-specific exposure was considered, more ADR reports for methylphenidate referred to children 4\u20136\u2009years and females 13\u201317\u2009years. Drugs for the treatment of nervous system disorders ranked first among \u201coff-label\u201d ADR reports.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our analysis underlines the importance of putting the number of ADR reports of a drug in context with its prescriptions. Additionally, differences in age- and sex-stratified analysis were observed which may be associated with age- and sex-specific diseases and, thus, drug exposure. The drugs most frequently included in \u201coff-label\u201d ADR reports differed from those most often used according to literature.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40360-021-00520-y","type":"journal-article","created":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T09:22:00Z","timestamp":1633598520000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Descriptive analysis of adverse drug reaction reports in children and adolescents from Germany: frequently reported reactions and suspected drugs"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8763-051X","authenticated-orcid":false,"given":"Diana","family":"Dubrall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1207-4168","authenticated-orcid":false,"given":"Sarah","family":"Leitzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0089-1494","authenticated-orcid":false,"given":"Irmgard","family":"Toni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1566-8156","authenticated-orcid":false,"given":"Julia","family":"Stingl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0788-0317","authenticated-orcid":false,"given":"Matthias","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6575-1452","authenticated-orcid":false,"given":"Antje","family":"Neubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8260-0891","authenticated-orcid":false,"given":"Bernhardt","family":"Sachs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,7]]},"reference":[{"issue":"23","key":"520_CR1","first-page":"393","volume":"115","author":"D Dubrall","year":"2018","unstructured":"Dubrall D, Schmid M, Ale\u0161ik E, et al. Frequent adverse drug reactions, and medication groups under suspicion. Dtsch Arztebl Int. 2018;115(23):393\u2013400.","journal-title":"Dtsch Arztebl Int."},{"issue":"2","key":"520_CR2","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1542\/peds.2012-0139","volume":"130","author":"FT Bourgeois","year":"2012","unstructured":"Bourgeois FT, Murthy S, Pinto C, et al. Pediatric versus adult drug trials for conditions with high pediatric disease burden. Pediatrics. 2012;130(2):285\u201392.","journal-title":"Pediatrics."},{"issue":"3","key":"520_CR3","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/bcp.12305","volume":"79","author":"PD Joseph","year":"2015","unstructured":"Joseph PD, Craig JC, Caldwell PHY. Clinical trials in children. Br J Clin Pharmacol. 2015;79(3):357\u201369.","journal-title":"Br J Clin Pharmacol."},{"issue":"46","key":"520_CR4","first-page":"781","volume":"112","author":"S Wimmer","year":"2015","unstructured":"Wimmer S, Neubert A, Rascher W. The Safety of Drug Therapy in Children. Dtsch Arztebl Int. 2015;112(46):781\u20137.","journal-title":"Dtsch Arztebl Int"},{"issue":"9","key":"520_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0044349","volume":"7","author":"A Oehme","year":"2012","unstructured":"Oehme A, Rashed AN, Hefele B, et al. Adverse drug reactions in hospitalised children in germany are decreasing: results of a nine year cohort-based comparison. PLoS ONE. 2012;7(9):e44349.","journal-title":"PLoS ONE"},{"key":"520_CR6","unstructured":"European Medicines Agency. Guideline on good pharmacovigilance practices (GVP) Product- or Population-Specific Considerations IV: Paediatric population. 2018. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-good-pharmacovigilance-practices-gvp-product-population-specific-considerations-iv_en-0.pdf. Accessed 25 Oct 2018."},{"issue":"6","key":"520_CR7","doi-asserted-by":"publisher","first-page":"481","DOI":"10.2165\/11597920-000000000-00000","volume":"35","author":"AN Rashed","year":"2012","unstructured":"Rashed AN, Wong ICK, Cranswick N, et al. Adverse Drug Reactions in Children--International Surveillance and Evaluation (ADVISE): a multicentre cohort study. Drug Saf. 2012;35(6):481\u201394.","journal-title":"Drug Saf."},{"key":"520_CR8","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1007\/s00103-019-03008-7","volume":"62","author":"H Knopf","year":"2019","unstructured":"Knopf H, Sargans G, Grams D, et al. Application of medicines and nutritional supplements in childhood and adolescence in Germany - Results from KiGGS Wave 2. Bundesgesundheitsbl. 2019;62:1215\u201324.","journal-title":"Bundesgesundheitsbl."},{"key":"520_CR9","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1186\/1471-2458-13-631","volume":"13","author":"H Knopf","year":"2013","unstructured":"Knopf H, Wolf IK, Sarganas G, et al. Off-label medicine use in children and adolescents: results of a population-based study in Germany. BMC Public Health. 2013;13:631.","journal-title":"BMC Public Health."},{"issue":"3","key":"520_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0024061","volume":"7","author":"RMD Smyth","year":"2012","unstructured":"Smyth RMD, Gargon E, Kirkham J, et al. Adverse drug reactions in children-a systematic review. PLoS ONE. 2012;7(3):e24061.","journal-title":"PLoS ONE."},{"issue":"4","key":"520_CR11","doi-asserted-by":"publisher","first-page":"327","DOI":"10.2165\/11319100-000000000-00000","volume":"33","author":"L Aagaard","year":"2010","unstructured":"Aagaard L, Weber CB, Hansen EH. Adverse drug reactions in the paediatric population in Denmark: a retrospective analysis of reports made to the Danish medicines agency from 1998 to 2007. Drug Saf. 2010;33(4):327\u201339.","journal-title":"Drug Saf."},{"issue":"8","key":"520_CR12","doi-asserted-by":"publisher","first-page":"669","DOI":"10.2165\/11591730-000000000-00000","volume":"3","author":"SM Wallerstedt","year":"2011","unstructured":"Wallerstedt SM, Brunl\u00f6f G, Sundstr\u00f6m A. Rates of spontaneous reports of adverse drug reactions for drugs reported in children: a cross-sectional study with data from the Swedish adverse drug reaction database and the Swedish prescribed drug register. Drug Saf. 2011;3(8):669\u201382.","journal-title":"Drug Saf."},{"key":"520_CR13","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1002\/pds.858","volume":"13","author":"M Ufer","year":"2004","unstructured":"Ufer M, Kimland E, Bergman U. Adverse drug reactions and off-label prescribing for paediatric outpatients: a one-year survey of spontaneous reports in Sweden. Pharmacoepidemiol Drug Saf. 2004;13:147\u201352.","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"6","key":"520_CR14","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.jped.2018.05.019","volume":"95","author":"E Costa Lima","year":"2019","unstructured":"Costa Lima E, Matos GC, Vieira JM, et al. Suspected adverse drug reactions reported for Brazilian children: cross-sectional study. J Pediatr (Rio J). 2019;95(6):682\u20138.","journal-title":"J Pediatr (Rio J)."},{"issue":"6","key":"520_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0155385","volume":"11","author":"R Rosli","year":"2016","unstructured":"Rosli R, Ming LC, Aziz NA, et al. A retrospective analysis of spontaneous adverse drug reactions reports relating to paediatric patients. PLoS ONE. 2016;11(6):e0155385.","journal-title":"PLoS ONE."},{"issue":"7","key":"520_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0132916","volume":"10","author":"YM Yu","year":"2015","unstructured":"Yu YM, Shin WG, Lee J, et al. Patterns of adverse drug reactions in different age groups: analysis of spontaneous reports by community pharmacists. PLoS ONE. 2015;10(7):e0132916.","journal-title":"PLoS ONE."},{"issue":"1","key":"520_CR17","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/pds.1679","volume":"18","author":"R Johann-Liang","year":"2009","unstructured":"Johann-Liang R, Wyeth J, Chen M, et al. Pediatric drug surveillance and the Food and Drug Administration's adverse event reporting system: an overview of reports, 2003\u20132007. Pharmacoepidemiol Drug Saf. 2009;18(1):24\u20137.","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"520_CR18","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s40272-014-0076-2","volume":"16","author":"KV Blake","year":"2014","unstructured":"Blake KV, Zaccaria C, Domergue F, et al. Comparison between paediatric and adult suspected adverse drug reactions reported to the European medicines agency: implications for pharmacovigilance. Pediatr Drugs. 2014;16:309\u201319.","journal-title":"Pediatr Drugs."},{"key":"520_CR19","unstructured":"European Medicines Agency. Legal framework: Pharmacovigilance. https:\/\/www.ema.europa.eu\/en\/human-regulatory\/overview\/pharmacovigilance\/legal-framework-pharmacovigilance."},{"key":"520_CR20","unstructured":"European Medicines Agency. Guideline on good pharmacovigilance practices (GVP) Module VI \u2013 Management and reporting of adverse reactions to medicinal products. EMA\/873138\/2011 Rev 2*. 2017. https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/guideline-good-pharmacovigilance-practices-gvp-module-vi-collection-management-submission-reports_en.pdf. Accessed 28 July 2017."},{"issue":"3","key":"520_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0230632","volume":"15","author":"D Dubrall","year":"2020","unstructured":"Dubrall D, Schmid M, Stingl J, et al. Angioedemas associated with renin-angiotensin system blocking drugs: Comparative analysis of spontaneous adverse drug reaction reports. PLoS ONE. 2020;15(3):e0230632.","journal-title":"PLoS ONE."},{"key":"520_CR22","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s40360-020-0392-9","volume":"21","author":"D Dubrall","year":"2020","unstructured":"Dubrall D, Just KS, Schmid M, et al. Adverse drug reactions in older adults: a retrospective comparative analysis of spontaneous reports to the German Federal Institute for Drugs and Medical Devices. BMC Pharmacol Toxicol. 2020;21:25.","journal-title":"BMC Pharmacol Toxicol."},{"key":"520_CR23","unstructured":"European Medicines Agency. EudraVigilance. https:\/\/www.ema.europa.eu\/en\/human-regulatory\/research-development\/pharmacovigilance\/eudravigilance."},{"key":"520_CR24","unstructured":"European Medicines Agency. Access to Eudravigilance data. https:\/\/www.ema.europa.eu\/en\/human-regulatory\/research-development\/pharmacovigilance\/eudravigilance\/access-eudravigilance-data."},{"key":"520_CR25","unstructured":"Medical Dictionary for Regulatory Activities (MedDRA). Introductory Guide MedDRA Version 22.1. 2019. https:\/\/admin.new.meddra.org\/sites\/default\/files\/guidance\/file\/000354_intguide_22.1.pdf . Accessed Sept 2019."},{"key":"520_CR26","unstructured":"European Medicines Agency. Public data from Article 57 database. https:\/\/www.ema.europa.eu\/en\/human-regulatory\/post-authorisation\/data-medicines-iso-idmp-standards\/public-data-article-57-database."},{"issue":"3","key":"520_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0247446","volume":"16","author":"S Leitzen","year":"2021","unstructured":"Leitzen S, Dubrall D, Toni I, et al. Analysis of the reporting of adverse drug reactions in children and adolescents in Germany in the time period from 2000 to 2019. PLoS ONE. 2021;16(3):e0247446.","journal-title":"PLoS ONE."},{"key":"520_CR28","unstructured":"National Association of Statutory Health Insurance Physicians and the regional Associations of Statutory Health Insurance Physicians. https:\/\/www.kbv.de\/html\/about_us.php."},{"key":"520_CR29","unstructured":"Central Research Institute of Ambulatory Health Care in Germany. https:\/\/www.zi.de\/."},{"issue":"1","key":"520_CR30","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s40264-013-0131-x","volume":"37","author":"T Bergvall","year":"2014","unstructured":"Bergvall T, Noren GN, Lidquist M. vigiGrade: a tool to identify well-documented individual case reports and highlight systematic data quality issues. Drug Saf. 2014;37(1):65\u201377.","journal-title":"Drug Saf."},{"issue":"9237","key":"520_CR31","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","volume":"356","author":"IR Edwards","year":"2000","unstructured":"Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356(9237):1255\u20139.","journal-title":"Lancet."},{"issue":"5","key":"520_CR32","doi-asserted-by":"publisher","first-page":"415","DOI":"10.2165\/11587540-000000000-00000","volume":"34","author":"K Star","year":"2011","unstructured":"Star K, Nor\u00e9n GN, Nordin K, et al. Suspected adverse drug reactions reported for children worldwide: an exploratory study using VigiBase. Drug Saf. 2011;34(5):415\u201328.","journal-title":"Drug Saf."},{"issue":"9","key":"520_CR33","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1007\/s00228-012-1255-0","volume":"68","author":"A Aldea","year":"2012","unstructured":"Aldea A, Garc\u00eda S\u00e1nchez-Colomer M, Fern\u00e1ndes Quintana E, et al. Paediatric adverse drug reactions reported to the Spanish Pharmacovigilance System from 2004 to 2009. Eur J Clin Pharmacol. 2012;68(9):1329\u201338.","journal-title":"Eur J Clin Pharmacol."},{"key":"520_CR34","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1517\/14740338.2014.939581","volume":"13","author":"C Ferrajolo","year":"2014","unstructured":"Ferrajolo C, Capuano A, Trifiro G, et al. Pediatric drug safety surveillance in Italian pharmacovigilance network: an overview of adverse drug reactions in the years 2001\u20132012. Expert Opin Drug Saf. 2014;13:9\u201320.","journal-title":"Expert Opin Drug Saf."},{"issue":"10","key":"520_CR35","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1080\/14740338.2016.1221921","volume":"15","author":"KO Cliff-Eribo","year":"2016","unstructured":"Cliff-Eribo KO, Sammons H, Choonara I. Systematic review of paediatric studies of adverse drug reactions from pharmacovigilance databases. Expert Opin Drug Saf. 2016;15(10):1321\u20138.","journal-title":"Expert Opin Drug Saf."},{"issue":"6","key":"520_CR36","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1046\/j.1525-1470.2000.01815.x","volume":"17","author":"JS Fluhr","year":"2000","unstructured":"Fluhr JS, Pfisterer S, Gloor M. Direct comparison of skin physiology in children and adults with bioengineering methods. Pediatr Dermatol. 2000;17(6):436\u20139.","journal-title":"Pediatr Dermatol."},{"key":"520_CR37","unstructured":"Akmatov MK, Hering R, Steffen A, et al. Aufmerksamkeitsdefizit\u2212\/Hyperaktivit\u00e4tsst\u00f6rung bei Kindern und Jugendlichen in der ambulanten Versorgung in Deutschland Teil 4 \u2013 Trends in der medikament\u00f6sen Versorgung im Zeitraum 2009 bis 2016. 2019. https:\/\/www.versorgungsatlas.de\/fileadmin\/ziva_docs\/94\/VA_19-02_Bericht_ADHS_Teil4_2019-03-06.pdf."},{"key":"520_CR38","unstructured":"European Medicines Agency. Press release: European Medicines Agency makes recommendations for safer use of Ritalin and other methylphenidate-containing medicines in the EU. 2009. https:\/\/www.ema.europa.eu\/en\/documents\/press-release\/european-medicines-agency-makes-recommendations-safer-use-ritalin-other-methylphenidate-containing_en.pdf. Accessed 22 Jan 2009."},{"key":"520_CR39","unstructured":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte. Risikobewertungsverfahren: Methylphenidathaltige Arzneimittel: Artikel 31-Verfahren. 2009. Methylphenidate: https:\/\/www.bfarm.de\/SharedDocs\/Risikoinformationen\/Pharmakovigilanz\/DE\/RV_STP\/m-r\/methylphenidat.html. Accessed 23 June 2009."},{"key":"520_CR40","unstructured":"Akmatov MK, Holstiege J, Hering R, et al. Die Aufmerksamkeitsdefizit\u2212\/Hyperaktivit\u00e4tsst\u00f6rung (ADHS) bei Kindern und Jugendlichen in der ambulanten Versorgung in Deutschland. Teil 3 \u2013 Identifizierung raumzeitlicher Cluster der Diagnosepr\u00e4valenz im Zeitraum 2009 bis 2016. https:\/\/www.versorgungsatlas.de\/fileadmin\/ziva_docs\/88\/VA_18-02_Bericht_ADHS_V1_2018-05-23_red.pdf."},{"key":"520_CR41","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.eurpsy.2018.11.001","volume":"56","author":"JJS Kooij","year":"2019","unstructured":"Kooij JJS, Bijlenga D, Salerno L, et al. Updated European Consensus Statement on diagnosis and treatment of adult ADHD. Eur Psychiatry. 2019;56:14\u201334.","journal-title":"Eur Psychiatry."},{"issue":"3","key":"520_CR42","first-page":"46","volume":"3","author":"K G\u00f6bel","year":"2018","unstructured":"G\u00f6bel K, Baumgarten F, Knutz B, et al. ADHS bei Kindern und Jugendlichen in Deutschland \u2013 Querschnittergebnisse aus KiGGS Welle 2 und Trends. J Health Monitoring. 2018;3(3):46\u201353.","journal-title":"J Health Monitoring."},{"key":"520_CR43","unstructured":"Wuppermann A, Schwandt H, Hering R, et al. Die Aufmerksamkeitsdefizit-Hyperaktivit\u00e4tsst\u00f6rung (ADHS) bei Kindern und Jugendlichen in der ambulanten Versorgung in Deutschland. Teil 2 - Zusammenhang zwischen ADHS-Diagnose und Medikationspr\u00e4valenzen und dem Einschulungsalter. https:\/\/www.versorgungsatlas.de\/fileadmin\/ziva_docs\/61\/VA-61-ADHS-Teil2-final.pdf."},{"key":"520_CR44","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13293-020-00308-5","volume":"11","author":"I Zucker","year":"2020","unstructured":"Zucker I, Pendergast BJ. Sex differences in pharmacokinetics predict adverse drug reactions in women. BMC Biology of Sex Differences. 2020;11:32.","journal-title":"BMC Biology of Sex Differences."},{"issue":"7","key":"520_CR45","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1111\/bcp.13923","volume":"85","author":"ST de Vries","year":"2019","unstructured":"de Vries ST, Denig P, Ekhart C, et al. Sex differences in adverse drug reactions reported to the National Pharmacovigilance Centre in the Netherlands: An explorative observational study. Br J Clin Pharmacol. 2019;85(7):1507\u201315.","journal-title":"Br J Clin Pharmacol."},{"issue":"4","key":"520_CR46","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-010433","volume":"6","author":"SK Inglis","year":"2016","unstructured":"Inglis SK, Carucci S, Garas P, et al. Prospective observational study protocol to investigate long-term adverse effects of methylphenidate in children and adolescents with ADHD: the Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects (ADDUCE) study. BMJ Open. 2016;6(4):e010433.","journal-title":"BMJ Open."},{"key":"520_CR47","unstructured":"Ritalin 10 mg Tabletten. Fachinformation. Stand der Information Oktober 2019. https:\/\/www.fachinfo.de\/api\/fachinfo\/pdf\/002958."},{"issue":"9","key":"520_CR48","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1002\/phar.1455","volume":"34","author":"WJ Lee","year":"2014","unstructured":"Lee WJ, Lee TA, Pickard S, et al. Drugs associated with adverse events in children and adolescents. Pharmacother. 2014;34(9):918\u201326.","journal-title":"Pharmacother."},{"key":"520_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1517\/14740338.2014.928692","volume":"13","author":"C Carnovale","year":"2014","unstructured":"Carnovale C, Brusadelli T, Zuccotti G, et al. The importance of monitoring adverse drug reactions in pediatric patients: the results of a national surveillance program in Italy. Expert Opin Drug Saf. 2014;13:1\u20138.","journal-title":"Expert Opin Drug Saf."},{"key":"520_CR50","unstructured":"Palivizumab: SPC: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/synagis-epar-product-information_en.pdf."},{"issue":"5","key":"520_CR51","doi-asserted-by":"publisher","DOI":"10.1542\/peds.110.5.e53","volume":"110","author":"TJ Moore","year":"2002","unstructured":"Moore TJ, Weiss SR, Kaplan S, et al. Reported adverse drug events in infants and children under 2 years of age. Pediatr. 2002;110(5):e53.","journal-title":"Pediatr."},{"key":"520_CR52","unstructured":"Arznei-telegramm. ADHS-MITTEL ATOMOXETIN (STRATTERA) STEIGERT SUIZIDALIT\u00c4T. 2005. https:\/\/www.arznei-telegramm.de\/html\/2005_11\/0511102_01.html."},{"key":"520_CR53","first-page":"1","volume-title":"Side-effects of anti-inflammatory drugs, advances in inflammation research","author":"JCP Weber","year":"1984","unstructured":"Weber JCP. Epidemiology of adverse reactions to nonsteroidal anti-inflammatory drugs. In: Rainsford KD, Velo GD, editors. Side-effects of anti-inflammatory drugs, advances in inflammation research. New York: Raven Press; 1984. p. 1\u20137."},{"key":"520_CR54","unstructured":"Fachinformation Etanercept\/Enbrel. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/enbrel-epar-product-information_de.pdf."},{"key":"520_CR55","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/sj.jp.7211352","volume":"25","author":"KA Lattimore","year":"2005","unstructured":"Lattimore KA, Donn SM, Kaciroti N, et al. Selective Serotonin Reuptake Inhibitor (SSRI) use during pregnancy and effects on the fetus and newborn: a meta-analysis. J Perinatol. 2005;25:595\u2013604.","journal-title":"J Perinatol."},{"issue":"9","key":"520_CR56","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1002\/pds.4242","volume":"26","author":"A Cantarutti","year":"2017","unstructured":"Cantarutti A, Merlino L, Giaquinto C, et al. Use of antidepressant medication in pregnancy and adverse neonatal outcomes: a population-based investigation. Pharmacoepidemiol Drug Saf. 2017;26(9):1100\u20138.","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"520_CR57","unstructured":"Robert Koch Institut. Beitr\u00e4ge zur Gesundheitsberichterstattung des Bundes Lebensphasenspezifische Gesundheit von Kindern und Jugendlichen in Deutschland - Ergebnisse des Nationalen Kinder- und Jugendgesundheitssurveys (KiGGS). Page 81\/82; https:\/\/www.rki.de\/DE\/Content\/Gesundheitsmonitoring\/Gesundheitsberichterstattung\/GBEDownloadsB\/KiGGS_SVR.pdf?__blob=publicationFile)."},{"issue":"9","key":"520_CR58","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/S0895-4356(02)00450-X","volume":"55","author":"J Hasford","year":"2002","unstructured":"Hasford J, Goettler M, Munter KH, et al. Physicians' knowledge and attitudes regarding the spontaneous reporting system for adverse drug reactions. J Clin Epidemiol. 2002;55(9):945\u201350.","journal-title":"J Clin Epidemiol."},{"issue":"5","key":"520_CR59","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","volume":"29","author":"L Hazell","year":"2006","unstructured":"Hazell L, Shakir SA. Under-reporting of adverse drug reactions. Drug Saf. 2006;29(5):385\u201396.","journal-title":"Drug Saf."},{"issue":"7","key":"520_CR60","doi-asserted-by":"publisher","first-page":"477","DOI":"10.2165\/00002018-200427070-00004","volume":"27","author":"N Mittmann","year":"2004","unstructured":"Mittmann N, Knowles SR, Gomez M, et al. Evaluation of the extent of under-reporting of serious adverse drug reactions. Drug Saf. 2004;27(7):477\u201387.","journal-title":"Drug Saf."},{"issue":"3","key":"520_CR61","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/pds.4726","volume":"28","author":"B Sachs","year":"2019","unstructured":"Sachs B, Dubrall D, Fischer-Barth W, et al. Drug-induced anaphylactic reactions in children: A retrospective analysis of 159 validated spontaneous reports. Pharmacoepidemiol Drug Saf. 2019;28(3):377\u201388.","journal-title":"Pharmacoepidemiol Drug Saf."}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-021-00520-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-021-00520-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-021-00520-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T10:27:53Z","timestamp":1633602473000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-021-00520-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,7]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["520"],"URL":"https:\/\/doi.org\/10.1186\/s40360-021-00520-y","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,7]]},"assertion":[{"value":"27 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study had been approved by the local ethics committee of the Medical Faculty of Bonn (009\/17). Consent to participate was not applicable. The Federal Institute for Drugs and Medical Devices (BfArM) as a national competent authority is granted with the highest level of access to EudraVigilance since one of the core duties of the BfArM is to analyse EudraVigilance data in order to fulfill its pharmacovigilance obligations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"56"}}